Medication info
Pregabalin Capsule 25 mg (Pregabalin)

Pregabalin Capsule 25 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›25mg / 1 capsule
Manufacturer / importer
Medica Korea Co., Ltd.
Appearance
A hard capsule with a light yellow upper part and a white lower part, containing white powder
Packaging
30 capsules per bottle
Approval status
Active

MFDS item code 201904423 · Approved 2019.06.27 · Insurance code 646004820

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medication is administered orally as pregabalin in the total daily dose divided into 2 doses, regardless of food. As this medication is excreted primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is excreted primarily by the kidneys as unchanged drug. As the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: starting dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Medica Korea Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medicine is used to treat peripheral and central neuropathic pain in adults and is also used as an adjunct in the treatment of partial seizures in epilepsy. It also helps alleviate the symptoms of fibromyalgia. Overall, this drug is used to improve various symptoms associated with neuropathic pain.

How to take

Adult dose

This medication is administered orally as pregabalin in the total daily dose divided into 2 doses, regardless of food. As this medication is excreted primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on each patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is excreted primarily by the kidneys as unchanged drug. As the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: starting dose 25, maximum dose 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; therefore, if there are any changes in mood or symptoms of depression during treatment, you should consult a doctor immediately. Patients with hypersensitivity to this drug or lactose intolerance should not take it. Diabetes patients should be cautious as they may need to adjust the dosage of blood sugar control medications due to weight gain. If there are symptoms of angioedema such as swelling around the face or mouth, stop taking the medication immediately and consult healthcare professionals. Older adults may experience more severe dizziness or drowsiness when taking this drug, so caution is advised when starting treatment. Blurred vision or changes in vision may occur, and if these symptoms arise, the medication should be discontinued and a doctor informed. If this drug is discontinued for a long time or abruptly, withdrawal symptoms such as insomnia, headache, and anxiety may occur, so dosage should be adjusted according to the doctor's instructions. Patients with a history of drug abuse should use this medication cautiously as they are at higher risk for abuse and should report any signs of abuse to healthcare professionals. Patients with reduced kidney function may require dosage adjustments. Patients with severe heart disease should consult healthcare professionals before taking this medication. Caution is warranted when taking this drug with opioid analgesics as it increases the risk of central nervous system depression. Patients with compromised respiratory function or elderly individuals may be at risk for severe respiratory depression; dosing should be according to a doctor's directives. Pregnant women should avoid taking this drug in early pregnancy due to the risk of fetal malformation, and women of childbearing age should use effective contraception. Breastfeeding women should consult a doctor regarding breastfeeding since this drug can be transmitted through breast milk. This medication may cause dizziness and drowsiness, so it is safest to avoid driving or operating hazardous machinery after taking it. Severe skin reactions can occur rarely, so if skin rashes or swelling appear, stop taking the medication immediately and consult healthcare professionals. In case of overdose, symptoms such as confusion, drowsiness, and disorientation may appear; treatment such as dialysis may be necessary if needed. Keep this medication out of reach of children or the elderly, and do not transfer it to another container.

Side effects

suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal ideation, pain, seizures, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, depression, elation, decreased libido, insomnia, depersonalization, hypersexuality, restlessness, anxiety, mood swings, emotional lability, emotional elevation, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, loss of impulse control, apathy, dizziness, drowsiness, ataxia, impaired coordination, balance disorders, amnesia, attention deficit, memory impairment, tremors, speech disorders, sensory abnormalities, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, language disorders, tremor, decreased reflexes, movement disorders, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, activity tremor, fainting, stupor, hypokinesia, olfactory disturbances, taste loss, dysgraphia, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field defects, photophobia, dry eyes, eyelid swelling, vision impairment, eye pain, eye fatigue, increased lacrimation, eye irritation, mydriasis, during vibration, changes in depth perception, strabismus, visual brightness, vertigo, auditory hypersensitivity, first-degree atrioventricular block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, abdominal bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasm, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, breast discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling intoxicated, altered sensation, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood glucose, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue edema, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, shock, anaphylaxis-like symptoms, Stevens-Johnson syndrome, polymorphous erythema, delirium, paralysis, mood disorders, state of confusion, agitation, restlessness, worsening of convulsions, sleep disturbances, skin disorders, bloody stools, increased BUN, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. Additionally, avoid storing it in places that are too hot or too cold, and store it at room temperature between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a light yellow upper part and a white lower part, containing white powder

Package unit

30 capsules per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.